← Back to Screener
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA)
Price$42.46
Favorite Metrics
Price vs S&P 500 (26W)9.75%
Price vs S&P 500 (4W)-12.05%
Market Capitalization$3.25B
P/E Ratio (Annual)55.07x
All Metrics
P/CF (Annual)23.55x
Book Value / Share (Quarterly)$7.44
P/TBV (Annual)5.66x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)45.45%
Cash Flow / Share (Quarterly)$1.79
Price vs S&P 500 (YTD)4.71%
Gross Margin (TTM)88.54%
Net Profit Margin (TTM)8.71%
EPS (TTM)$0.74
10-Day Avg Trading Volume0.64M
EPS Excl Extra (TTM)$0.74
EPS (Annual)$0.75
ROI (Annual)10.40%
Gross Margin (Annual)88.54%
Net Profit Margin (5Y Avg)-64.55%
Cash / Share (Quarterly)$5.43
P/E Basic Excl Extra (TTM)55.07x
Revenue Growth QoQ (YoY)64.95%
P/E Normalized (Annual)55.07x
ROA (Last FY)7.73%
Revenue Growth TTM (YoY)60.09%
EBITD / Share (TTM)$1.00
ROE (5Y Avg)-7.06%
Operating Margin (TTM)11.40%
Cash Flow / Share (Annual)$1.79
P/B Ratio5.73x
P/B Ratio (Quarterly)5.51x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)4.55x
ROA (TTM)8.63%
EV / EBITDA (TTM)39.15x
EPS Incl Extra (Annual)$0.75
Current Ratio (Annual)3.79x
Quick Ratio (Quarterly)3.09x
3-Month Avg Trading Volume0.60M
52-Week Price Return118.65%
EV / Free Cash Flow (Annual)22.61x
P/E Incl Extra (TTM)55.07x
Revenue / Employee (TTM)$2
Tangible BV / Share (Quarterly)$7.24
P/S Ratio (Annual)4.80x
Asset Turnover (Annual)0.89x
52-Week High$50.03
Operating Margin (5Y Avg)-82.13%
EPS Excl Extra (Annual)$0.75
CapEx CAGR (5Y)41.14%
Tangible BV CAGR (5Y)65.91%
26-Week Price Return18.50%
Quick Ratio (Annual)3.09x
13-Week Price Return13.50%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.79x
Enterprise Value$3,084.096
Asset Turnover (TTM)0.99x
Book Value / Share Growth (5Y)10.21%
Revenue / Employee (Annual)$2
Inventory Turnover (Annual)1.91x
Pretax Margin (Annual)13.12%
Cash / Share (Annual)$5.43
3-Month Return Std Dev37.43%
Gross Margin (5Y Avg)85.56%
Net Income / Employee (TTM)$0
ROE (Last FY)10.40%
EPS Basic Excl Extra (Annual)$0.75
P/FCF (TTM)23.82x
Receivables Turnover (TTM)23.64x
EV / Free Cash Flow (TTM)22.61x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$0.74
Receivables Turnover (Annual)23.64x
ROI (TTM)11.48%
P/S Ratio (TTM)4.80x
Pretax Margin (5Y Avg)-80.54%
Revenue / Share (Annual)$8.58
Tangible BV / Share (Annual)$7.24
Forward P/E34.39x
Price vs S&P 500 (52W)83.56%
P/E Ratio (TTM)55.07x
Year-to-Date Return8.85%
5-Day Price Return-5.07%
EPS Normalized (Annual)$0.75
ROA (5Y Avg)-5.00%
Net Profit Margin (Annual)8.71%
Month-to-Date Return-6.75%
Cash Flow / Share (TTM)$-0.06
EBITD / Share (Annual)$1.00
EPS Growth (3Y)-34.04%
Operating Margin (Annual)11.40%
P/CF (TTM)23.55x
ROI (5Y Avg)-7.06%
P/E Excl Extra (TTM)55.07x
EPS Basic Excl Extra (TTM)$0.74
P/TBV (Quarterly)5.66x
P/B Ratio (Annual)5.51x
Inventory Turnover (TTM)1.91x
Pretax Margin (TTM)13.12%
Book Value / Share (Annual)$7.44
Price vs S&P 500 (13W)10.63%
Beta0.04x
P/FCF (Annual)23.82x
Revenue / Share (TTM)$8.28
ROE (TTM)11.48%
52-Week Low$19.62
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.31
4.31
4.29
4.29
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares | 4.80x | 60.09% | 88.54% | — | $42.46 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for cardiovascular diseases. Its pipeline includes three lead candidates: Rilonacept, abiprubart, and Vixarelimab, with primary operations in the United States.